-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US8887051006 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 2M |
|---|---|
| PE Ratio | None |
| Target Price | 210 |
| Beta | 2.01 |
| Dividend Yield | None |
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TIVC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026